CD73, and more recently CD38, expression on tumor cells have been shown to confer resistance to anti-PD-1, as activation of T cells and PD-1 blockade upregulates the expression of A2AR, making these cells more susceptible to adenosine-mediated suppression [131]. The gene discussed is CD38; the disease is neoplasm.